Previous 10 | Next 10 |
2024-02-29 14:24:12 ET DENVER, Colo., Feb 29, 2024 ( 247marketnews.com )- After quietly trading sideways, today, Lava Therapeutics N.V. (NASDAQ: LVTX ) shot straight up from below $2.25 to a high of $3.41. It’s pulled back to $3.12, up $0.96 (+44.44%), 3.4M shares. LVTX...
2024-01-26 09:19:36 ET Losers: TC BioPharm ( TCBP ) -21% . Mobilicom Limited ( MOB ) -21% announces $2.95 Million registered direct offering . LAVA Therapeutics ( LVTX ) -14% . Evaxion Biotech ( EVAX ) -13% . Nxu ( NXU ) -13% ...
2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-25 08:11:38 ET More on LAVA Therapeutics Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics Read the full article on Seeking Alpha For further det...
2024-01-25 07:32:06 ET DENVER, Colo., Jan. 25, 2023 (www.247marketnews.com)- LAVA Therapeutics NV (NASDAQ: LVTX) stated, this morning, that... For further details see: LAVA Therapeutics (NASDAQ: LVTX) is Flowing on Merck Collaboration News
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAV...
2023-11-16 07:17:43 ET More on LAVA Therapeutics Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics For further details see: LAVA Therapeutics GAAP EPS of -$0...
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2 Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody ® platform as a monotherapy in advanced EGFR expres...
The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...
LAVA Therapeutics N.V. (LVTX) is expected to report $-0.48 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
LAVA Therapeutics N.V. Website:
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma delta T cell eng...
UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024 Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1 LAVA-1266 on track for Q2 2024 IND sub...